West Pharmaceutical SVP granted RSUs and options

West Pharmaceutical Services senior vice president Shane Alden Campbell reported equity compensation grants consisting of restricted stock units and stock options.

Rhea-AI Filing Summary

West Pharmaceutical Services senior vice president Shane Alden Campbell reported equity compensation grants consisting of restricted stock units and stock options. He acquired 1,131 restricted stock units, each representing the right to receive one share of West common stock, and 2,691 stock options with a right to buy West shares.

Both the restricted stock units and the stock options vest in four equal annual installments beginning on March 1, 2027, meaning the awards become exercisable or deliverable over time rather than all at once. These are non-cash, equity-based compensation awards and do not reflect any open-market stock purchases or sales.

Insider Trade Summary

Grant/Award: 3,822 shares

Grant/Award 2 txns

Insider Campbell Shane Alden

Role SVP, Proprietary Segment

Type	Security	Shares	Price	Value
Grant/Award	Rst. Stock Unit	1,131	$0.00	$0.00
Grant/Award	Stock Option (Right to Buy)	2,691	$0.00	$0.00

Holdings After Transaction: Rst. Stock Unit — 1,131 contracts (Direct); Stock Option (Right to Buy) — 2,691 contracts (Direct)

Footnotes (3)

1. F1. Each restricted stock unit represents a contingent right to receive one share of WST common stock.
2. F2. The restricted stock units vest in four equal annual installments beginning on March 1, 2027.
3. F3. The stock option vests in four equal annual installments beginning on March 1, 2027.

FAQ

What insider transaction did West Pharmaceutical (WST) report for Shane Alden Campbell?

West Pharmaceutical reported that SVP Shane Alden Campbell received equity awards, including 1,131 restricted stock units and 2,691 stock options. These awards are part of his compensation and do not involve buying or selling shares on the open market.

How many restricted stock units did Shane Alden Campbell receive from West Pharmaceutical (WST)?

Shane Alden Campbell received 1,131 restricted stock units. Each unit represents a contingent right to receive one share of West Pharmaceutical common stock, subject to vesting over time starting March 1, 2027, in four equal annual installments.

What are the vesting terms of the restricted stock units granted by West Pharmaceutical (WST)?

The 1,131 restricted stock units vest in four equal annual installments beginning on March 1, 2027. This schedule means 25% of the units become deliverable each year over four years, aligning the award with longer-term employment and company performance.

What stock options were granted to Shane Alden Campbell by West Pharmaceutical (WST)?

Shane Alden Campbell was granted 2,691 stock options, described as a “Stock Option (Right to Buy).” These options give him the right to purchase West Pharmaceutical shares, subject to vesting in four equal annual installments starting March 1, 2027.

Do the West Pharmaceutical (WST) Form 4 transactions involve open-market buying or selling?

The transactions reflect grants of restricted stock units and stock options, not open-market trades. Both awards were reported with a transaction code for grants or awards and a zero dollar price per share, indicating non-cash compensation rather than market purchases or sales.

When do Shane Alden Campbell’s stock options from West Pharmaceutical (WST) vest?

The 2,691 stock options vest in four equal annual installments beginning on March 1, 2027. Each year, 25% of the options become exercisable, creating a multi-year incentive structure tied to continued service and potential long-term value creation.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/03/2026 - 11:28 AM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Campbell Shane Alden

(Last) (First) (Middle)

530 HERMAN O. WEST DRIVE

(Street)

EXTON PA 19341

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
WEST PHARMACEUTICAL SERVICES INC [ WST ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, Proprietary Segment

3. Date of Earliest Transaction (Month/Day/Year)
03/01/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Rst. Stock Unit	(1)	03/01/2026		A		1,131		(2)	(2)	Common Stock	1,131	$0	1,131	D
Stock Option (Right to Buy)	$254.34	03/01/2026		A		2,691		(3)	03/01/2036	Common Stock	2,691	$0	2,691	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of WST common stock.

2. The restricted stock units vest in four equal annual installments beginning on March 1, 2027.

3. The stock option vests in four equal annual installments beginning on March 1, 2027.

	/s/ Caitlin Hippeli, as an agent for Shane A. Campbell	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.